Kiniksa Pharmaceuticals International, plc Logo

Kiniksa Pharmaceuticals International, plc

Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.

KNSA | US

Overview

Corporate Details

ISIN(s):
BMG5269C1010
LEI:
Country:
United States of America
Address:
23 OLD BOND STREET, FLOOR 3, LONDON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kiniksa Pharmaceuticals is a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for debilitating diseases with significant unmet medical needs. The company's portfolio is centered on innovative, immune-modulating assets. Its pipeline includes investigational therapies for conditions such as recurrent pericarditis, addressing diverse patient needs through novel treatments. Kiniksa operates with a patient-centric mission, aiming to deliver therapies to individuals with limited or no available treatment options.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kiniksa Pharmaceuticals International, plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kiniksa Pharmaceuticals International, plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kiniksa Pharmaceuticals International, plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America MGNX
MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI

Talk to a Data Expert

Have a question? We'll get back to you promptly.